Pancreatic Enzyme Replacement Therapy
The question
To ask the Secretary of State for Health and Social Care, if he will take steps to ensure that (a) patients requiring Creon are updated on the availability of that medication and (b) local guidance issued by (i) his Department and (ii) NHS England is shared with patients.
Answered by Karin Smyth
The Department has been working with suppliers, NHS England, and national clinical specialists to address the current supply issues with Creon, which is a brand of pancreatic enzyme replacement therapy. Comprehensive guidance has been issued to the National Health Service and is being regularly reviewed and updated as the supply situation changes. This guidance includes information clinicians can share with patients, and refers to advice from patient groups aimed at supporting patients in managing the supply issues and addressing their questions.
The Department has not issued any local guidance on this supply issue, but has issued a National Patient Safety Alert in December 2024, with an action for integrated care boards to put in place a local mitigation plan for instances when patients are unable to obtain stock from their community pharmacy or dispensing general practice. In all cases of medicines supply issues, healthcare professionals should endeavour to communicate any supply issues and relevant information about resupply dates and the proposed management plan clearly with patients. They should also undertake counselling to support affected patients where possible.
Verbatim has judged this answer against the question that was actually asked — answered, partly answered, or evaded. Sign in to see the verdict →